You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
岸迈生物1.2亿美元C轮融资 郑志刚跟投
阿思达克 03-23 12:13
专注於开发创新双抗药物的临床阶段生物制药公司岸迈生物公布,完成1.2亿美元C轮融资,由招银国际CMBI及韩国未来资产基金Mirae Asset Financial Group共同领投,弘毅投资、鱼鹰资管、燕创资本、Octagon Capital、新世界(00017.HK)执行副主席兼行政总裁郑志刚,及上湾资本等投资人共同参与,现有投资机构如德诚资本、国投创新、夏尔巴投资和潜龙投资积极跟投。

公司表示,是次筹集的资金将用於推进岸迈生物的EMB-01、EMB-02和EMB-06正在进行的人体临床研究,并拓展公司新型双特异性抗体等生物药的产品管线。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account